TY - JOUR
T1 - Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy
T2 - pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma
AU - Siddiqi, Tanya
AU - Coutre, Steven
AU - McKinney, Matthew
AU - Barr, Paul M.
AU - Rogers, Kerry
AU - Mokatrin, Ahmad
AU - Valentino, Rudy
AU - Szoke, Anita
AU - Deshpande, Sanjay
AU - Zhu, Angeline
AU - Arango-Hisijara, Israel
AU - Osei-Bonsu, Kojo
AU - Wang, Michael
AU - O’Brien, Susan
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This pooled analysis from nine clinical trials of ibrutinib in CLL and MCL (N = 1178) evaluated patterns of these AEs. Any grade arthralgia, myalgia, and musculoskeletal pain occurred in 18%, 10%, and 6% of patients, respectively. AEs were primarily low-grade (grade 1/2: 97‒99%) and occurred during the first year of treatment; most resolved (67%–80%) at first occurrence. Few (<5%) patients required ibrutinib dose modification; no patients discontinued ibrutinib due to these AEs. Among patients evaluated for concomitant medication use, all those receiving concomitant medications after the first AE occurrence experienced AE resolution. These data suggest that these AEs were not treatment-limiting during ibrutinib therapy.
AB - Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This pooled analysis from nine clinical trials of ibrutinib in CLL and MCL (N = 1178) evaluated patterns of these AEs. Any grade arthralgia, myalgia, and musculoskeletal pain occurred in 18%, 10%, and 6% of patients, respectively. AEs were primarily low-grade (grade 1/2: 97‒99%) and occurred during the first year of treatment; most resolved (67%–80%) at first occurrence. Few (<5%) patients required ibrutinib dose modification; no patients discontinued ibrutinib due to these AEs. Among patients evaluated for concomitant medication use, all those receiving concomitant medications after the first AE occurrence experienced AE resolution. These data suggest that these AEs were not treatment-limiting during ibrutinib therapy.
KW - arthralgia
KW - chronic lymphocytic leukemia
KW - Ibrutinib
KW - mantle cell lymphoma
KW - musculoskeletal pain
KW - myalgia
UR - http://www.scopus.com/inward/record.url?scp=85126064168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126064168&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2038372
DO - 10.1080/10428194.2022.2038372
M3 - Article
C2 - 35227147
AN - SCOPUS:85126064168
SN - 1042-8194
VL - 63
SP - 1580
EP - 1588
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -